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Background: Plasmodium vivax is the most widespread human malaria in tropical and subtropical countries,
including the Republic of Korea. Vivax malaria is characterized by hypnozoite relapse and long latency infection by
the retained liver stage of P. vivax, and somewhat surprisingly, little is known of the liver stage antigens of this
parasite. Here, we report for the first time the characterization of a liver stage antigen of P. vivax (PvLSA).
Methods: Five peptides located inside PvLSA were synthesized, and specific anti-sera to the respective peptides
were used to localize PvLSA on P. vivax parasites in human liver cells by immunofluorescence. Western blotting and
enzyme-linked immunosorbent assay were performed using the five peptides and sera collected from vivax malaria
patients and from normal healthy controls.
Results: PvLSA was localized on P. vivax parasites in human liver cells. Vivax malaria-infected patients were detected
using the five peptides by western blotting. Furthermore, the peptides reacted with the sera of vivax malaria
patients.
Conclusions: These results suggest that PvLSA may function during the liver stage of P. vivax.
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Plasmodium vivax is the most widespread human mal-
aria, and afflicts several hundred million people annually.
It is endemic to tropical and subtropical countries of the
Americas, Africa, and Asia, including the Republic of
Korea (ROK) [1-3]. Unlike P. falciparum, P. vivax is
characterized by hypnozoite relapse in the liver. After
being bitten by a P. vivax-infected mosquito, sporozoites
enter hepatocytes, where most develop into schizonts
that result in primary illness. However, some remain as
hypnozoites, which can become active months or even
years later, and cause relapse after resolution of the pri-
mary illness. Several factors have been suggested to lead
to hypnozoite development, for example, a cold ambient
temperature, the number of infecting sporozoites, the
specific strain of the mosquito vector or P. vivax [4-6].* Correspondence: jykim-malaria@nih.go.kr
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reproduction in any medium, provided the orHowever, the mechanisms responsible for hypnozoite
development and their activation are not known.
A vaccine and a diagnostic method based on antigens
specific to the liver stage of P. vivax are needed in order
to control vivax malaria, since asymptomatic carriers in
latency contribute to disease transmission. In falciparum
malaria, a recombinant anti-sporozoite subunit vaccine
(RTS,S/AS01) targeting circumsporozoite protein (CSP)
has shown best performance among vaccines developed to
date, though Phase III trials are ongoing [7]. In addition,
the detection of human carriers in the latent stage caused
by hypnozoites is important in many countries, including
the ROK, where the control strategy for vivax malaria is
moving from intervention toward elimination. Therefore,
an understanding of molecules specific for the liver stage
could help overcome the challenge posed by vivax malaria
in the setting of disease elimination.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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novel antigen expressed at the pre-erythrocytic stage [8].
A number of studies have demonstrated the potential of
LSA-3 as a vaccine and serodiagnosis candidate. B- and
T-cell epitopes have been characterized in LSA-3 [9],
and LSA-3 antigenicity has been demonstrated in
several immuno-epidemiological studies conducted in P.
falciparum malaria-exposed populations [10]. Moreover,
an enzyme-linked immunosorbent assay (ELISA) based
on recombinant LSA-3 has been developed as a sero-
diagnostic test for P. falciparum in Myanmar [11]. On
the other hand, little is known about the molecular cha-
racteristics of the liver stage of P. vivax, and the majority
of studies conducted, since Garnham identified the pre-
erythrocytic stage of P. vivax in human liver in 1947
[12], focused on the biology of hypnozoites.
Synthetic peptides derived from antigens of Plasmo-
dium spp. provide practical advantages for vaccine de-
velopment [13], evaluations of antigenicity [14,15], and
surveys of immunologic profiles in malaria-exposed po-
pulations [16]. Furthermore, ELISA tests developed for
peptides of some promising antigens now have improved
performances [17].
Therefore, we synthesized peptides that span all liver
stage antigens of P. vivax (PvLSA), and evaluated the
antigenicities of these peptides by Western blotting.
Finally, the efficacies of ELISA for these peptides were
determined based on its ability to detect blood samples
from vivax malaria patients.Methods
Ethics statements
The study was performed in the ROK and in Thailand,
and was approved by the ethics committee of the
Korean National Institute of Health (Approval number:Figure 1 Amino acid sequences of PvLSA and a schematic diagram o
bioinformatic software packages, are underlined (P1-5, P = peptide).2009-01CON-01-4R). An approval form was used to
obtain written informed consent from each participant.
In addition, all participants provided permission for
the sampling of 5 ml of blood.Blood samples
Blood samples, which were collected in EDTA tubes,
were obtained from 65 patients diagnosed with vivax
malaria at local health centers (Gang-wha, Paju, Gimpo)
from March to August. Microscopic examinations of
Giemsa-stained thick and thin blood films were used to
confirm diagnoses. Samples were also obtained from 10
asymptomatic and aparasitemic healthy volunteers con-
firmed as being P. vivax negative by microscopic exa-
mination and nested-PCR.Selection and synthesis of antigenic peptides on
Plasmodium vivax liver stage antigen
Here we used the liver stage antigen gene of the P. vivax
Sal-1 strain (PvLSA; Accession No. XP_001615328). The
open reading frame (ORF) of PvLSA was identified from a
cDNA library of Plasmodium vivax Korean isolates, and
4,521 nucleotides were predicted to encode a polypeptide
consisting of 1,507 amino acid residues. The molecular
weight of the mature protein was 173.4 kDa, as calculated
by Statistical Analysis of Protein Sequences (SAPS, https://
www.ebi.ac.uk/Tools/seqstats/saps/). To select peptide can-
didates with high antigenicity, we used the following B-cell
epitope mapping programs: BepiPred, which is based on
propensity scale methods (http://www.cbs.dtu.dk/services/
BepiPred/) [18] and BCPreds, which is based on machine
learning methods (http://ailab.cs.iastate.edu/bcpreds/) [19].
These programs revealed five peptides, P1-5 (Figure 1),
which were subsequently synthesized either without or with
ovalbumin conjugates by Peptron Inc. (ROK).f PvLSA peptides. Selected peptides of P. vivax LSA, identified using
Figure 2 Immunolocalization of PvLSA in P. vivax sporozoites. Specific anti-sera to P1-5 and CSP (circumsporozoite protein) reacted with
P. vivax sporozoites in hepatocytes from day 1 to day 3 post infection. (Green, peptides 1–5 and CSP; blue, DAPI)
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P. vivax sporozoites were prepared at the Armed Forces
Research Institute of Medical Sciences (AFRIMS; Thailand),
as described previously [20,21]. Briefly, sporozoites
were collected from the salivary glands of Anopheles
dirus (Bangkok Colony) mosquitoes fed the blood of
vivax malaria patients. Sporozoites, in an aseptic solution
containing 200 U/ml penicillin and 200 μg/ml strepto-
mycin, were centrifuged and counted. Subsequently, they
were inoculated into HC-04 cells (a human hepatocyte cell
line) that had been cultured in complete medium (MEM:
Ham’s F12 Gibco BRL, 1:1 v/v) supplemented with 10%
fetal bovine serum (Gibco BRL), 100 U/ml penicillin, and
100 μg/ml streptomycin at 37°C for 48 h. HC-04 cells were
harvested on days 1, 2, and 3 after sporozoite inoculation.
3After washing, cells were spread as a monolayer on
cytospin slides (ThermoShandon, USA).
Immunofluorescence assay (IFA)
To determine whether PvLSA was expressed in liver stage
parasites, we performed an immunofluorescence assay
(IFA) using HC-04 cells and specific anti-sera to the five
peptides at the Armed Forces Research Institute of Medical
Sciences (AFRIMS; Thailand). Anti-sera specific to the re-
spective peptides (P1-5) were purchased from Peptron Inc.
(ROK). The slides prepared as described above were first
fixed with cold acetone for IFA. Next, anti-P1, P2, P3, P4,
and P5 rabbit sera, and the monoclonal antibody of the
circumsporozoite protein type VK210 were used at
concentrations of 10 μg/ml for IFA staining. Second-
ary antibodies were fluoresced using isothiocyanate-
conjugated anti-rabbit and human IgG (Invitrogen, USA),
and fluorescence was visualized by confocal microscopy
(Leica, Germany). An anti-serum to the circumsporozoite
antigen expressed in P. vivax parasites during the early liver
stage was used as a positive control.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blotting
Briefly, the five ovalbumin-conjugated peptides were sepa-
rated by SDS-PAGE and stained with Coomassie Blue.
Separated peptide fractions were electroblotted onto
Immobilon-P Transfer membranes (Millipore, USA),
which were then blocked with 5% skim milk (Wako,
Japan). Subsequently, membranes were probed overnight
with vivax malaria sera samples diluted in 5% skim milk.
Bound antibodies were reacted with horseradish
peroxidase-conjugated secondary antibodies and detected
using the West-Q Chemiluminescent Substrate Kit (Gen-
DEPOT, USA).
Enzyme-linked immunosorbent assay (ELISA)
The 60 blood samples from vivax malaria patients and 10
samples from healthy controls were subjected to ELISA aspreviously described with modifications [22]. Peptides with-
out ovalbumin (P1, 2, 3, and 5) (500 ng) were coated onto
96-well microplates (Nunc, Denmark) overnight at 4°C,
and then incubated with respective blood samples at a dilu-
tion of 1:200 (peptide 4, which showed weak reaction in a
localization study was excluded). Second antibody binding
was detected using horseradish peroxidase-conjugated anti-
human IgG (Bethyl Laboratories, Inc., USA) (1:5000) and
TMV (Sigma-Aldrich, USA). Optical densities were mea-
sured at 450 nm. The cut-off value of each peptide was cal-
culated by adding 3 times the standard deviation of 10
blood samples from healthy people to the mean OD value.
Samples with an OD value higher than the appropriate cut-
off value were considered vivax malaria positive.
Results and discussion
Five antigenic peptides in a liver stage antigen of P. vivax
(PvLSA) were predicted by two bioinformatic programs
(Figure 1), and then synthesized with or without ovalbumin
conjugates. These PvLSA peptides of Sal-I strain appeared
to be conserved among the PvLSAs of other strains, includ-
ing Brazil I, India VII, Mauritania I, North Korean, and
South Korean strains according to the determination of sin-
gle nucleotide polymorphisms (SNPs) of PvLSAs in Plas-
moDB. Total 32 SNPs were found in PvLSAs of these six
strains, and 17 of the 32 were non-synonymous SNPs; the
non-synonymous/synonymous ratio was 1.13, meaning that
PvLSA is a genetically diverse protein. However, 3 SNPs
and other 29 SNPs were located in intron and other non-
synthesized regions, respectively (Additional file 1: Figure
S1). Thus, the selected peptides were considered conserved
among P. vivax strains. As shown in Figure 2, the pur-
chased specific anti-sera for P 1–5 reacted with P. vivax
parasites in the liver stage, and reactions between specific
anti-sera and the parasites in human liver cells were even
stronger than those between specific anti-sera and CSP;
anti-serum to P4 showed relatively weak reactions as com-
pared with those of other peptides. Reactions between spe-
cific anti-sera to peptides and P. vivax parasites in liver
cells continued from day 1 to day 3 post-parasite infection,
indicating that the five peptides spanning PvLSA are trans-
lated in the liver stage of P. vivax and retained during the
early liver stage. Although longer culture of HC-04 cells
with P. vivax is needed to determine whether reactions
continued to the latent liver stage, these localization results
demonstrate the first identification of a liver stage antigen
of P. vivax.
Because LSA-3 of P. falciparum (PfLSA-3) is a promising
candidate for a vaccine and for the serodiagnosis of falcip-
arum malaria, we hypothesized that the five synthesized
small peptides were antigenic, and thus, could be used to
detect antibodies specific to PvLSA in blood samples from
malaria-infected individuals. To test this hypothesis, we
performed western blotting using these five peptides
(A) (B) (C)
P1  P2  P3  P4  P5 P1   P2   P3   P4   P5 P1   P2   P3   P4   P5
Figure 3 Antigenicity of peptides 1–5 by Western blotting. (A) Ovalbumin-conjugated peptides (P1-5) were separated by SDS-PAGE. (B) Sera
from vivax malaria patients reacted with ovalbumin-conjugated peptides 1–5. (C) No reaction was observed between the ovalbumin-conjugated
peptides 1–5 probed with the sera of healthy individuals.
Table 1 Positive rate of vivax malaria by ELISAs with
peptides (P1, 2, 3 and 5) spanning on PvLSA
Peptides P1 P2 P3 P5
No. of positive sample (%) 40 (66.7) 42 (70.0) 45 (75.0) 50 (83.3)
No. of negative sample (%) 20 (33.3) 18 (30.0) 15 (25.0) 10 (16.7)
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tients exhibiting clinical symptoms and diagnosed as
having vivax malaria by microscopic examination at
health centers in the ROK. As shown in Figure 3,
strong reactions between P1-5 and blood samples
from vivax patients were observed (B), whereas no re-
action was observed in the blood samples of healthy
controls (C). As expected, blood samples of vivax mal-
aria patients showed no bands when only ovalbumin
was loaded (data not shown). These results indicate
that the five peptides are antigenic.
Next, in order to analyze the antibody responses to
PvLSA peptides in naturally infected individuals, ELISAs
with the peptides were conducted using sera from 60 pa-
tients infected with P. vivax. As shown in Table 1, the
peptides spanning PvLSA reacted with blood samples
from patients of vivax malaria. In detail, the cut-off
values of ELISAs for P1, 2, 3, and 5 were 0.15, 0.155,
0.129, and 0.153, respectively. ELISAs for P1, P2, P3 and
P5 detected 66.7, 70.0, 75.0, and 83.3% of P. vivax infec-
tion samples as vivax malaria positive, respectively
(Table 1). In particular, ELISA with P5 showed best per-
formance on detecting antibodies specific to P. vivax
among the ELISAs with the peptides. This performance
of antibody detection by PvLSA peptides is better than
that by liver stage antigen of P. falciparum (70.7%)
which has detected antibodies specific to P. falciparum
in falciparum malaria patients in previous study [11]. In
addition, this positive rate of the ELISA with P5 (83.3%)
was higher compared to that of ELISA with CSP of
P. vivax (11.26-21.01%), a promising vaccine candidate of
vivax malaria, using samples from vivax malaria patients in
ROK [23].
Although PvLSA and liver stage antigens of P.
falciparum (PfLSA-1 and PfLSA-3) are antigenic pro-
teins expressed by malaria parasites in hepatocytes,
PvLSA and PfLSAs are distinct at the genomic sequence
level. PvLSA is homologous with the liver stage antigen ofP. cynomolgi (PCYB_092710, PlasmDB), but not with two
liver stage antigens of P. falciparum. In addition, PvLSA
does not have the specific repeat and non-repeat domains
of the liver stage antigens of P. falciparum. Although
PvLSA and the liver stage antigens of falciparum malaria
(PfLSA-1 and PfLSA-3) have different functions in the
liver stages of vivax and falciparum malaria.
Studies on molecules expressed by malarial parasites
during the liver stage, such as, on liver stage antigen,
could help identify the mechanisms responsible for
the long-term survival of vivax parasites in the human
liver and of latent infection. In addition, serodiagnos-
tic methods and vaccines based on synthetic peptides
have been recently developed for parasitic diseases
and other pathogenic infections [16,24]. Therefore,
we suggest further studies on the five peptides are
warranted to provide more insight on the liver
stage.Conclusions
We report for the first time, the characterization of a
liver stage antigen of P. vivax using five synthesized
peptides located on PvLSA. Specific anti-sera produced
using the respective peptides were found to react with
P. vivax parasites in human liver cells. Furthermore,
peptides specifically reacted with sera from vivax ma-
laria patients by ELISA. Based on these results, further
studies would provide more insight on the liver stage
of vivax malaria.
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